The FDA Decides July 7... Wall Street Thinks This $35 Stock Doubles

On July 7, the FDA will make a single decision on a single $35 stock. Eight Wall Street analysts think that when it does, Vera Therapeutics stock is worth more than double where it trades today.

Here is the part that separates this from every other biotech lottery ticket: the drug already works.

The big Phase 3 trial did not fail. It did not squeak by. It crushed expectations. A 46% reduction in the protein destroying these patients' kidneys. A 42% improvement over the placebo. This is not a coin flip on whether the science is real. The science already won. This is a coin flip on a rubber stamp.

Those are two very different bets.

The stock is Vera Therapeutics, ticker V, a $2.5 billion biotech most investors have never heard of.

The Previous FDA Play on Vera Therapeutics Stock: +150%

The last biotech setup like this one worked out extremely well. A $1 stock with a similar pending FDA decision, OTLK, was trading for 74 cents at the time. Twelve days later, it hit $1.79. That is a gain of 150%.

There are no guarantees the same thing happens here. But that trade gives you a clear picture of the explosive potential when a dated FDA announcement lines up correctly.

What Disease Does Vera Therapeutics' Drug Target?

Vera's drug targets a kidney disease called IgA Nephropathy. Your own immune system slowly attacks your kidneys. Patients spill protein into their urine for years. Eventually, a huge chunk of them end up on dialysis or needing a full kidney transplant.

It is one of the most common causes of kidney failure in younger adults. For decades, there was not much doctors could do about it.

Vera's drug goes after the problem upstream. It turns down the immune signal that starts the whole attack in the first place. Instead of mopping up the damage, it shuts off the faucet.

Phase 3 Results That Crushed It

The ORIGIN Phase 3 trial did not just meet expectations. It blew past them.

In kidney disease, knocking protein down like that is exactly what keeps patients off dialysis, or at the very least delays kidney failure significantly.

The data was strong enough that Vera filed for approval immediately. The FDA put the drug on the fast track, granting it priority review. That is how we got a hard decision date: July 7, 2026.

What Do Wall Street Analysts Say About Vera Therapeutics Stock?

The smart money has already done the homework. This is not some ignored micro-cap with zero coverage.

Eight Wall Street analysts rate Vera Therapeutics stock. The consensus: Strong Buy. Not a hold. Not a wait-and-see. A strong buy.

Going into the decision, the stock trades around $35 a share.

• Lowest analyst target: $56
• Average price target: $83.50
• Most bullish target: $110

Think about what those numbers mean. The most pessimistic analyst covering this stock still thinks it goes up 60%. The average analyst says it more than doubles.

How Do You Trade a Stock Around an FDA Decision Date?

When the FDA approves a drug, the stock jumps instantly. The big funds have algorithms tied straight into the news feeds. When the headline hits the wire, the stock has already gapped up. It happens in seconds.

You are not going to read the press release, calmly log into your account, and press buy. If you want to be in something like this, the rule is simple: own the stock before the date, not after the news.

The reward goes to the people who took the position while the outcome was uncertain. The people waiting for confirmation are the ones buying shares after the fact.

Size It Right

Do not go 200% long in this trade. Size your position so the normal market swings do not knock you out before the announcement.

Forget the Perfect Entry

This is not a typical technical breakout. The stock had been drifting lower since the beginning of the year. But real momentum is showing up. Over a recent two-week stretch, the stock moved 23% to 24% higher. The price is back above both the 50-day moving average and the 200-day moving average.

The chart is improving, but the position itself is the point, not the pattern.

What Could Still Go Wrong

This setup sounds clean, but it is not without risk. The FDA does not always say yes.

They can delay the decision date. They can ask the company for more data. They can flat-out reject the drug entirely. If they reject it, the outcome would not be good for the stock price. That is the nature of the bet.

Trading the News, Not the Decade

The July 7 ruling is just the first step toward full approval. Do I have any intention of holding this stock into 2027? I do not.

I am trading the upcoming news event.

The reason this setup works: the hard science has already cleared the bar. The Phase 3 trial worked. Wall Street rates Vera Therapeutics stock a strong buy. And there is a hard date on the calendar.

That is about as clean of a setup as you will find in the biotech sector. If the approval comes through, it would not be a surprise to see this stock jump to $50, $60, and beyond in a hurry.